Compare Cigna Corp (CI) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs Nutanix Inc — how do they compare? Cigna Corp trades at $302.78 (market cap $80.25B), while Nutanix Inc trades at $55.32 (market cap $14.99B). The key difference: Cigna Corp is far larger — about 5.4× Nutanix Inc's market cap, and Cigna Corp pays a 2.06% dividend while Nutanix Inc pays none. Which is the better fit depends on your goals.
| CI | NTNX | |
|---|---|---|
Market Cap | $80.25B | $14.99B |
Sector | Health | Technology |
52-Week High | $311.00 | $81.12 |
52-Week Low | $244.41 | $34.41 |
Enterprise Value | $103.35B | $14.51B |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $304.50, up 3.76% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $7.79 exceeding the $7.60 estimate. Valuation metrics appear attractive with a P/E of 12.91 and P/S of 0.29. Recent news highlights strategic AI investments in pharmacy services and positive sector sentiment.
The investment case centers on undervaluation, earnings momentum, and dividend yield, though risks include regulatory challenges and moderating cash flow. With a consensus price target of $339.82 implying 11.6% upside, Wall Street maintains a bullish stance, but investors should weigh execution risks against growth initiatives.
Nutanix (NTNX) trades at $55.22, up 0.78% on the day, reflecting positive momentum. The stock exhibits a bullish technical trend with strong moving average support and is trading near key resistance at $56. Fundamentally, the company demonstrates robust revenue growth, with Q3 2026 results beating expectations, and maintains a high gross profit margin of 87.09%. Recent news highlights strategic partnerships and NVIDIA certification for its AI infrastructure solutions.
The outlook for NTNX is positive, driven by consistent earnings beats, strong analyst consensus (62.5% Buy ratings), and a $57.80 price target suggesting modest upside. Key risks include its high valuation multiples (P/E of 58.39) and execution challenges in a competitive cloud software market. Investor sentiment is buoyed by its positioning in hybrid multicloud and AI growth areas.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
